Sign inJoin waitlistJoin the waitlist

Andrea Apolo

Acting Deputy Chief · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Clinical Center at the National Institutes of Health
Present

Research

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2021 · 1,483 citations
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Journal of Clinical Oncology · 2017 · First of 17 authors · Corresponding · 485 citations
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
The Lancet Oncology · 2018 · Last of 18 authors · Corresponding · 469 citations

James Gulley
20 papers
JR
Jonathan Rosenberg
16 papers
Piyush Agarwal
16 papers
DB
Dean Bajorin
14 papers
NS
Nicholas Simon
14 papers · 2 as a fellow
SN
Scot Niglio
14 papers · 1 as a fellow
WD
William Dahut
14 papers
Matthew Galsky
13 papers
Ashish Kamat
12 papers
Elias Chandran
12 papers
Matthew Milowsky
12 papers
Jason Efstathiou
11 papers

Grants

Bladder Cancer Program
National Cancer Institute · ZIA
Contact PI · $9.4M · Division of Basic Sciences - Nci
Targeting the MET Pathway in Urothelial Carcinoma
National Cancer Institute · ZIA
Contact PI · $7.9M · Division of Basic Sciences - Nci
Rare Genitourinary Tumors Projects
National Cancer Institute · ZIA
Contact PI · $4.6M · Division of Basic Sciences - Nci

Clinical trials

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2028
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Principal investigator · Recruiting
National Cancer Institute (NCI)
2022–2042